Abstract: The present disclosure relates to a system that utilizes Power over Ethernet (PoE) to supply low voltage direct current (DC) power to a PoE enabled track lighting system. The system facilitates communications with individual track heads located in a PoE enabled low voltage track channel so that the operational characteristics of the individual track heads can be controlled (e.g., dim, brighten, change color), so that feedback on functional status of individual track heads can be obtained, and so that total system current can be regulated. The PoE track lighting system includes a PoE track interface (PTI) device that receives current and communication signals. The PTI device receives the digital communication signals, converts them to a second digital commination signal in a format more suitable for transmission along the communication conductors in the track channel, and transmits the second digital communication signal to the communication conductors of the track channel.

Abstract: The present disclosure relates to a system that utilizes Power over Ethernet (PoE) to supply low voltage direct current (DC) power to a PoE enabled track lighting system. The system facilitates communications with individual track heads located in a PoE enabled low voltage track channel so that the operational characteristics of the individual track heads can be controlled (e.g., dim, brighten, change color), so that feedback on functional status of individual track heads can be obtained, and so that total system current can be regulated. The PoE track lighting system includes a PoE track interface (PTI) device that receives current and communication signals. The PTI device receives the digital communication signals, converts them to a second digital commination signal in a format more suitable for transmission along the communication conductors in the track channel, and transmits the second digital communication signal to the communication conductors of the track channel.

Abstract: The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.

Abstract: The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above.

Abstract: The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.

Abstract: A system has a lighting fixture has a first connector electrically coupled to a power supply, the first connector being separately electrically coupled to a load, an occupancy sensor having a second connector adapted and configured to engage the first connector, the occupancy sensor being capable of detecting a presence of a person within a monitored space, the first and second connectors forming a disconnect for the lighting fixture, and a switch located in the occupancy sensor arranged to electrically couple the power supply and the load when the first connector is coupled to the second connector and when the occupancy sensor detected a person's presence within the monitored space.

Abstract: The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders.

Abstract: An electrical power pack may include a first power switch and a cycle control to cycle between the first power switch and a second power switch. An electrical power pack may include a first power switch and a delay element to delay an operation of the first power switch. A power pack system may include a first power switch to operate in response to a constant-on control and a second power switch to operate in response to an automatic control. A power pack system may include a first power switch to operate in response to a manual-on control, and a second power switch to operate in response to an automatic-on control.

Abstract: An occupancy sensing system includes a vacate input to cause the system to turn lights on without substantial delay when a monitored space becomes occupied after turning the load off in response to the vacate input. A special vacate input may be eliminated by determining, in response to a manual-off input, if the space has been vacated. A dead time may be included to prevent the lights from being turned back on by movement that is detected as occupants vacate the monitored space after pressing a vacate or manual-OFF button.

Abstract: The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders.

Abstract: The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from 4 to 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in a subject after oral administration comprising orally administering a pharmaceutical composition as described above.

Abstract: The present invention includes methods for preventing endometrial hyperplasia associated with estrogen therapy through the administration of a progestin agent. The methods presented may include starting the administration of a progestin agent at a high dose, and then lowering the dose.

Abstract: An electrical power pack may include a first power switch and a cycle control to cycle between the first power switch and a second power switch. An electrical power pack may include a first power switch and a delay element to delay an operation of the first power switch. A power pack system may include a first power switch to operate in response to a constant-on control and a second power switch to operate in response to an automatic control. A power pack system may include a first power switch to operate in response to a manual-on control, and a second power switch to operate in response to an automatic-on control.

Abstract: The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above.

Abstract: An electrical power pack may include a first power switch and a cycle control to cycle between the first power switch and a second power switch. An electrical power pack may include a first power switch and a delay element to delay an operation of the first power switch. A power pack system may include a first power switch to operate in response to a constant-on control and a second power switch to operate in response to an automatic control. A power pack system may include a first power switch to operate in response to a manual-on control, and a second power switch to operate in response to an automatic-on control.

Abstract: The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide.

Abstract: A wireless demand response endpoint includes a power switch and a wireless receiver to control the power switch in response to a wireless demand signal. The wireless demand signal may be transmitted at the same premises as the endpoint. One or more wireless endpoints at the premises may be configured to respond to the wireless demand signal. The wireless demand signal may be transmitted automatically, manually, or in other modes. Power switching may be on/off, dimming, etc.

Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

Abstract: The present invention discloses an apparatus and method for converting a low voltage occupancy sensor to a powered stand-alone unit. The invention uses a low voltage occupancy sensor mounted in an upper portion of a housing with its associated low voltage wiring terminating in a terminal block. An attachable corresponding lower housing is provided with a power pack adapted to connect with the low voltage terminal block wherein once combined the upper and lower housing portions combine to form an integral powered stand-alone sensor unit.

Abstract: An electrical power pack may include a first power switch and a cycle control to cycle between the first power switch and a second power switch. An electrical power pack may include a first power switch and a delay element to delay an operation of the first power switch. A power pack system may include a first power switch to operate in response to a constant-on control and a second power switch to operate in response to an automatic control. A power pack system may include a first power switch to operate in response to a manual-on control, and a second power switch to operate in response to an automatic-on control.